X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The two rounds of financing will be used to accelerate the CMC production and IND filings of three antibody drugs (Tavo111, Tavo103, and Tavo101) developed by the company based on its TavoPrecise antibody platform.
Lead Product(s): Tavo111
Therapeutic Area: Oncology Product Name: Tavo111
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: YuanBio Venture Capital
Deal Size: $20.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing March 22, 2021
Details:
The objective of the agreement is to develop a novel first-in-class immune-modulator bispecific antibody for auto-immune and inflammatory-related conditions, using DuoBody® technology, proprietary platform of Genmab A/S of Denmark.
Lead Product(s): Bispecific antibodies
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Recipient: Genmab
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 25, 2020
Details:
The objective of the alliance is to co-develop a combination therapy of involving Yisheng's & Tavotek's lead assets YS-ON-001/002 and Tavo-201/203 for cancer treatment.
Lead Product(s): YS-ON-001,YS-ON-002,Tavo-201
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Yisheng Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
